Specialty Physician Associates | Bethlehem, PA
Status and phase
Conditions
Treatments
About
Randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR-064.
Full description
The purpose of this study is to determine the safety and effectiveness of CYR-064 in a randomized, double-blinded, placebo-controlled trial to determine the safety and efficacy of CYR064.
The study will take approximately 32 weeks which will include a 4-week screening period to evaluate if participants are right for the Study, followed by a 24-week Treatment Period, and a 1 week follow up after participants have completed the Study. About 150 subjects will participate in this study in about 25 research sites in the United States.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Vulnerable patients. Any condition or abnormality (including clinical laboratory, physical examination, or vital sign abnormalities), current or past, that, in the opinion of the Investigator, would compromise the efficacy evaluation, safety of the patient, or would interfere with or complicate study procedures or assessments.
Primary purpose
Allocation
Interventional model
Masking
150 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Krista Geoffrion; Rick Geoffrion
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal